Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents

10.1093/bja/aem063

Adams, 1998, Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine, J Neurosci, 18, 5545, 10.1523/JNEUROSCI.18-14-05545.1998

10.1016/S0165-0173(99)00046-6

10.1038/nrd2217

10.1001/archpsyc.57.3.270

10.1124/jpet.110.173880

10.1038/clpt.1987.193

10.1016/j.neuroimage.2012.09.037

10.1001/archgenpsychiatry.2007.37

10.1007/s00213-007-0774-3

10.1016/S0006-8993(98)00926-3

Duncan, 2000, Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism, J Pharmacol Exp Ther, 293, 8

10.1016/S0006-8993(97)01390-5

10.1007/PL00005334

10.1016/0006-3223(95)00046-1

Farde, 1995, Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients, J Clin Psychopharmacol, 15, 19S, 10.1097/00004714-199502001-00004

10.1016/0014-2999(84)90404-7

10.1038/sj.npp.1301547

10.1016/j.neuroscience.2010.02.057

10.1038/clpt.1993.146

10.1038/sj.mp.4001093

10.1038/1099

10.1007/s002130051049

10.1001/archpsyc.1994.03950030035004

10.1097/00000542-200405000-00006

10.1177/0269881107077712

10.1007/s00213-005-0020-9

10.1016/S0306-4522(02)00652-8

10.1088/0031-9155/37/7/010

10.1176/appi.ajp.159.4.599

10.1016/j.neuroimage.2009.10.072

10.1007/s00213-010-2137-8

10.1038/sj.npp.1300479

Moghaddam, 1997, Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J Neurosci, 17, 2921, 10.1523/JNEUROSCI.17-08-02921.1997

10.1038/sj.npp.1300342

10.1176/ajp.156.6.869

10.1017/S1461145708009814

Rasmussen CE, Williams CKI (2006) Gaussian Processes for Machine Learning, MIT Press, Cambridge, MA.

Schmidt, 1996, Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade, J Pharmacol Exp Ther, 277, 1541

10.1038/mp.2011.171

10.1176/appi.ajp.161.9.1620

10.1002/hbm.20035

10.1016/S0893-133X(98)00072-4

10.1016/S0924-977X(96)00039-9

10.1002/(SICI)1099-1492(199706/08)10:4/5<237::AID-NBM475>3.0.CO;2-X